دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
Cobain, Erin F. MD 1,,; Hayes, Daniel F. MD 1,
doi : 10.1200/JCO.22.00702
Volume 40(32) pgs. 3673-3784 November 10, 2022
Just and Equitable Enrollment to Pivotal Clinical Trials in Hematologic Malignancies.
Chandhok, Namrata S. MD 1,; Sekeres, Mikkael A. MD, MS 1,,
doi : 10.1200/JCO.22.01547
Primary CNS Lymphoma: Progress With Dose-Intensive Consolidation.
Rubenstein, James L. MD, PhD 1,,
doi : 10.1200/JCO.22.01337
AB The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice. (C) 2022 American Society of Clinical Oncology
Toward a Better Understanding of the Differential Impact of Heart Failure Phenotypes After Breast Cancer.
Reding, Kerryn W. PhD, MPH, BSN 1,2,; Cheng, Richard K. MD, MS 3; Barac, Ana MD, PhD 4; Vasbinder, Alexi PhD, BSN 5; Hovsepyan, Gayane MD 6; Stefanick, Marcia PhD 7; Simon, Michael S. MD, MPH 6
doi : 10.1200/JCO.22.00111
Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study.
Houillier, Caroline MD 1; Dureau, Sylvain PharmD 2; Taillandier, Luc MD, PhD 3; Houot, Roch MD, PhD 4,; Chinot, Olivier MD, PhD 5,; Molucon-Chabrot, Cecile MD 6; Schmitt, Anna MD 7,; Gressin, Remy MD 8,; Choquet, Sylvain MD 9,; Damaj, Gandhi MD, PhD 10,11,; Peyrade, Frederic MD, PhD 12,; Abraham, Julie MD 13,; Delwail, Vincent MD 14; Gyan, Emmanuel MD, PhD 15,; Sanhes, Laurence MD 16; Cornillon, Jerome MD, PhD 17,18,; Garidi, Reda MD 19; Delmer, Alain MD, PhD 20,; Al Jijakli, Ahmad MD 21; Morel, Pierre MD 22,23,; Waultier, Agathe MD 24; Paillassa, Jerome MD 25; Chauchet, Adrien MD 26; Gastinne, Thomas MD 27,; Laadhari, Mouna MD 28; Plissonnier, Anne-Sophie MSc 29; Feuvret, Loic MD 30; Cassoux, Nathalie MD, PhD 31; Touitou, Valerie MD, PhD 32,; Ricard, Damien MD, PhD 33; Hoang-Xuan, Khe MD, PhD 1,; Soussain, Carole MD, PhD 34,,; on behalf of the LOC Network for CNS Lymphoma
doi : 10.1200/JCO.22.00491
AB Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.
Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.
Bachelot, Thomas MD, PhD 1,,; Cottu, Paul MD, PhD 2,; Chabaud, Sylvie PhD 3; Dalenc, Florence MD 4; Allouache, Djelila MD 5; Delaloge, Suzette MD 6,; Jacquin, Jean-Philippe MD 7; Grenier, Julien MD 8,; Venat Bouvet, Laurence MD 9; Jegannathen, Apurna MD 10; Campone, Mario MD, PhD 11,; Del Piano, Francesco MD 12; Debled, Marc MD 13; Hardy-Bessard, Anne-Claire MD, PhD 14,; Giacchetti, Sylvie MD 15,; Mouret-Reynier, Marie-Ange MD 16; Barthelemy, Philippe MD 17,; Kaluzinski, Laure MD 18; Mailliez, Audrey MD 19,; Legouffe, Eric MD 20; Sephton, Matthew MD 21,; Bliss, Judith MD 22,; Canon, Jean-Luc MD 23; Penault-Llorca, Frederique MD, PhD 24,; Lemonnier, Jerome PhD 25; Cameron, David MD 26,; Andre, Fabrice MD, PhD 6,
doi : 10.1200/JCO.21.02179
AB PURPOSE: Everolimus, an oral inhibitor of the mammalian target of rapamycin, improves progression-free survival in combination with endocrine therapy (ET) in postmenopausal women with aromatase inhibitor-resistant metastatic breast cancer. However, the benefit of adding everolimus to ET in the adjuvant setting in early breast cancer is unknown.
Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention.
Hantel, Andrew MD 1; Kohlschmidt, Jessica PhD 2; Eisfeld, Ann-Kathrin MD, PhD 3,; Stock, Wendy MD 4,; Jacobson, Sawyer MS 5; Mandrekar, Sumithra PhD 5,; Larson, Richard A. MD 4,; Stone, Richard M. MD 1,; Lathan, Christopher S. MD, MPH 1,; DeAngelo, Daniel J. MD, PhD 1,; Byrd, John C. MD 6,; Abel, Gregory A. MD, MPH 1,
doi : 10.1200/JCO.22.00307
Representativeness in acute leukemia clinical research is essential for achieving health equity. The National Cancer Institute's mandate for Comprehensive Cancer Centers (CCCs) to define and assume responsibility for cancer control and treatment across a geographic catchment area provides an enforceable mechanism to target and potentially remediate participatory inequities.
Are Pivotal Clinical Trials for Drugs Approved for Leukemias and Multiple Myeloma Representative of the Population at Risk?.
Casey, Mycal DO, MPH 1; Odhiambo, Lorriane PhD, MPH 2; Aggarwal, Nidhi BS 3; Shoukier, Mahran MD 4; Garner, Jamani BS 2; Islam, K.M. MBBS, PhD, MPH 2,3; Cortes, Jorge E. MD 4,,
doi : 10.1200/JCO.22.00504
There are significant disparities in care and outcomes for patients with leukemias and multiple myeloma (MM). To evaluate the extent to which clinical trials (CTs) match the demographic and geographic diversity of populations affected by leukemias and MM.
Metastatic Rhabdomyosarcoma: Results of the European Paediatric Soft Tissue Sarcoma Study Group MTS 2008 Study and Pooled Analysis With the Concurrent BERNIE Study.
Schoot, Reineke A. MD, PhD 1,,; Chisholm, Julia C. BMBCh, PhD 2,; Casanova, Michela MD 3,; Minard-Colin, Veronique MD, PhD 4,; Geoerger, Birgit MD, PhD 4,5,; Cameron, Alison L. MB ChB, MRCP, FRCR, PGC(Ed) 6; Coppadoro, Beatrice BSc 7; Zanetti, Ilaria BSc 7; Orbach, Daniel MD 8,; Kelsey, Anna MRCS, LRCP, FRCPath 9,; Rogers, Timothy MD, MBBCh, FCS(SA), FCS(paed), FRCS(paed) 10; Guizani, Cecile MSc 11,; Elze, Markus PhD 11,; Ben-Arush, Myriam MD 12; McHugh, Kieran MB, BCh, BAO (NUI), FRCR, FRCPI, FFRRCPI 13; van Rijn, Rick R. MD, PhD 14,; Ferman, Sima MD, PhD 15; Gallego, Soledad MD, PhD 16,; Ferrari, Andrea MD 3; Jenney, Meriel MD 17,; Bisogno, Gianni MD, PhD 7,; Merks, Johannes H.M. MD, PhD 1,
doi : 10.1200/JCO.21.02981
Outcome for patients with metastatic rhabdomyosarcoma (RMS) is poor. This study presents the results of the MTS 2008 study with a pooled analysis including patients from the concurrent BERNIE study.
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment.
Garbe, Claus MD 1,,; Keim, Ulrike PhD 1; Amaral, Teresa MD, PhD 1,; Berking, Carola MD 2,; Eigentler, Thomas K. MD 3,; Flatz, Lukas MD 1,; Gesierich, Anja MD 4,; Leiter, Ulrike MD 1,; Stadler, Rudolf MD 5,; Sunderkotter, Cord MD 6,; Tuting, Thomas MD 7,; Utikal, Jochen MD 8,9,; Wollina, Uwe MD 10; Zimmer, Lisa MD 11,12,; Zouboulis, Christos C. MD, PhD 13,; Ascierto, Paolo A. MD 14,; Eggermont, Alexander M.M. MD, PhD 15,16,17,; Grob, Jean-Jacques MD 18,; Hauschild, Axel MD 19,; Sekulovic, Lidija Kandolf MD, PhD 20,; Long, Georgina V. MD, PhD 21,22,; Luke, Jason J. MD 23,; Michielin, Olivier MD 24,; Peris, Ketty MD 25,26,; Schadendorf, Dirk MD 11,12,; Kirkwood, John M. MD 27,; Lorigan, Paul C. MD 28,; on behalf of the Central Malignant Melanoma Registry (CMMR)
doi : 10.1200/JCO.22.00202
The first randomized trial of adjuvant treatment with checkpoint inhibitor in stage II melanoma reported a significant reduction in risk of tumor recurrence. This study evaluates two independent data sets to further document survival probabilities for patients with primary stage I and II melanoma.
FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group.
Hofheinz, Ralf-Dieter MD 1,,; Merx, Kirsten MD 1; Haag, Georg M. MD 2,; Springfeld, Christoph MD 2,; Ettrich, Thomas MD 3,; Borchert, Kersten MD 4,; Kretzschmar, Albrecht MD 5,; Teschendorf, Christian MD 6; Siegler, Gabriele MD 7,; Ebert, Matthias P. MD 1,8,9,; Goekkurt, Eray MD 10,; Mahlberg, Rolf MD 11,; Homann, Nils MD 12,; Pink, Daniel MD 13,14,; Bechstein, Wolf MD 15,; Reichardt, Peter MD 16,; Flach, Hagen 17,; Gaiser, Timo MD 18,; Battmann, Achim MD 19,; Oduncu, Fuat S. MD 20; Loose, Maria PhD 21; Sookthai, Disorn MSc 21,; Pauligk, Claudia PhD 21; Goetze, Thorsten O. MD 21,22,; Al-Batran, Salah-Eddin MD 21,22,
doi : 10.1200/JCO.22.00380
High pathologic complete response (pCR) rates and comparably good survival data were seen in a phase II trial combining perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy with trastuzumab for resectable, esophagogastric adenocarcinoma (EGA). The current trial evaluates the addition of trastuzumab and pertuzumab to FLOT as perioperative treatment for human epidermal growth factor receptor 2-positive resectable EGA.
Primary Retroperitoneal Lymph Node Dissection for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumor-N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary?.
Tachibana, Isamu MD 1,; Kern, Sean Q. MD 1; Douglawi, Antoin MD 1; Tong, Yan MS 2; Mahmoud, Mohammad MD 1; Masterson, Timothy A. MD 1; Adra, Nabil MD 3,; Foster, Richard S. MD 1; Einhorn, Lawrence H. MD 3,; Cary, Clint MD, MPH 1
doi : 10.1200/JCO.22.00118
According to National Comprehensive Cancer Network guidelines, adjuvant chemotherapy (AC) has been advocated after primary retroperitoneal lymph node dissection (RPLND) to reduce the risk of relapse in pathologic nodal (pN) stage pN2 or pN3, whereas surveillance is preferred for pN1. We sought to explore the oncologic efficacy of primary RPLND alone for pathologic stage II in nonseminomatous germ cell tumors (NSGCTs) to reduce overtreatment with chemotherapy.
Linking the European Organisation for Research and Treatment of Cancer Item Library to the Common Terminology Criteria for Adverse Events.
Gilbert, Alexandra MBBS, BSc, PhD 1,,; Piccinin, Claire MSc 2; Velikova, Galina PhD 1,; Groenvold, Mogens MD, PhD, DSc 3; Kulis, Dagmara MA 2; Blazeby, Jane M. BSc, MB ChB, MD 4; Bottomley, Andrew PhD 2
doi : 10.1200/JCO.21.02017
The European Organisation for Research and Treatment of Cancer (EORTC) Item Library is an interactive online platform currently composed of 950 unique items (questions) derived from 67 patient-reported outcome (PRO) questionnaires. PROs complement clinician adverse event (AE) reporting classifications like the Common Terminology Criteria for Adverse Events (CTCAE). This work aims to create a standardized framework using the CTCAE to systematically classify symptomatic AEs from the EORTC Item Library through linking individual items to corresponding AEs.
Considerations for the Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy.
Zhang, Jindong MD; Liu, Maoyu MD
doi : 10.1200/JCO.22.00726
Reply to J. Zhang et al.
Steenbeek, Miranda P. MD, PhD; van Bommel, Majke H.D. MD; Bulten, Johan MD, PhD; Hermens, Rosella P.M.G. PhD; IntHout, Joanna PhD; de Hullu, Joanne A. MD, PhD
doi : 10.1200/JCO.22.01266
